Fulgent Genetics (FLGT) Net Cash Flow (2015 - 2026)

Fulgent Genetics (FLGT) has 12 years of Net Cash Flow data on file, last reported at -$26.8 million in Q1 2026.

• Quarterly Net Cash Flow fell 320.99% year-over-year to -$26.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$44.0 million (down 445.91% YoY) and the FY2025 annual result came in at -$5.1 million, up 88.0% from the prior year.
• Net Cash Flow advanced to -$26.8 million in Q1 2026 per FLGT's latest filing, from -$67.5 million in the prior quarter.
• The five-year high for Net Cash Flow was $188.2 million in Q1 2022, with the low at -$213.7 million in Q2 2022.
• Average Net Cash Flow over 5 years is -$8.3 million, with a median of -$2.8 million recorded in 2024.
• The widest YoY moves for Net Cash Flow: up 519.49% in 2025, down 2342.95% in 2025.
• Fulgent Genetics' Net Cash Flow stood at -$89.0 million in 2022, then jumped by 114.89% to $13.3 million in 2023, then sank by 120.86% to -$2.8 million in 2024, then slumped by 2342.95% to -$67.5 million in 2025, then surged by 60.31% to -$26.8 million in 2026.
• Business Quant data shows FLGT's Net Cash Flow at -$26.8 million in Q1 2026, -$67.5 million in Q4 2025, and $29.7 million in Q3 2025.